Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 2, 2013, Pages 314-320

  Ringdén, Olle ^a   Remberger, Mats ^a   Holmberg, Katarina ^a   Edeskog, Charlotta ^a   Wikström, Marie ^a   Eriksson, Britta ^a   Finnbogadottir, Sigrun ^a   Fransson, Karin ^a   Milovsavljevic, Ruza ^a   Omazic, Brigitta ^a   Svenberg, Petter ^a   Mattsson, Jonas ^a   Svahn, Britt Marie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Home care; Neutropenia; Oral nutrition

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; RAPAMYCIN; TACROLIMUS; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CALORIC INTAKE; CANCER RECURRENCE; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HERPES ZOSTER; HOME CARE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NUTRITIONAL STATUS; OVERALL SURVIVAL; PATIENT SAFETY; PRESCHOOL CHILD; RADIATION DOSE FRACTIONATION; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOME CARE SERVICES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84872597648     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.011     Document Type: Article

References (39)

1. Buckner C.D., Clift R.A., Sanders J.E., et al. Protective environment for marrow transplant recipients: a prospective study. Ann Intern Med 1978, 89:893-901.
2. Mahmoud H.K., Schaefer U.W., Schuning F., et al. Laminar air flow versus barrier nursing in marrow transplant recipients. Blut 1984, 49:375-381.
3. Passweg J.R., Rowlings P.A., Atkinson K.A., et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998, 21:1231-1238.
4. Skinhoj P., Jacobsen N., Hoiby N., Faber V. Strict protective isolation in allogenic bone marrow transplantation: effect on infectious complications, fever and graft versus host disease. Scand J Infect Dis 1987, 19:91-96.
5. Svahn B.M., Bjurman B., Myrback K.E., et al. Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplant 2000, 26:1057-1060.
6. Svahn B.M., Remberger M., Myrback K.E., et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002, 100:4317-4324.
7. Russell J.A., Poon M.C., Jones A.R., et al. Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease. Lancet 1992, 339:38-40.
8. Svahn B.M., Remberger M., Heijbel M., et al. Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition. Transplantation 2008, 85:1000-1007.
9. Ringden O., Ruutu T., Remberger M., et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994, 83:2723-2730.
10. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
11. Diedrich B., Remberger M., Shanwell A., et al. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005, 45:1064-1072.
12. Ringden O., Remberger M., Persson U., et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995, 15:619-625.
13. Beelen D.W., Haralambie E., Brandt H., et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992, 80:2668-2676.
14. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989, 73:1729-1734.
15. Schaffer M., Aldener-Cannava A., Remberger M., et al. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 2003, 62:243-250.
16. Ringden O., Remberger M., Runde V., et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999, 94:455-464.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Fine J., Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
19. Mattsson J., Westin S., Edlund S., Remberger M. Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease. Bone Marrow Transplant 2006, 38:629-633.
20. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
21. Goldberg J., Jacobsohn D.A., Zahurak M.L., Vogelsang G.B. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:101-107.
22. Sparrelid E., Hagglund H., Remberger M., et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998, 22:795-800.
23. Jones J.M., Wilson R., Bealmear P.M. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971, 45:577-588.
24. van Bekkum D.W., Roodenburg J., Heidt P.J., van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974, 52:401-404.
25. Storb R., Prentice R.L., Buckner C.D., et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983, 308:302-307.
26. Bostrom L., Ringden O., Gratama J.W., et al. A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1990, 5:321-326.
27. Reddy P., Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 2003, 17:187-194.
28. Carlens S., Ringden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998, 22:755-761.
29. Storb R., Prentice R.L., Sullivan K.M., et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983, 98:461-466.
30. Svahn B.M., Ringden O., Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:511-516.
31. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
32. Ringden O., Labopin M., Gluckman E., et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996, 18:921-929.
33. Weiden P.L., Sullivan K.M., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1533.
34. Aschan J., Ringden O., Sundberg B., et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991, 7:113-119.
35. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
36. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
37. Ringden O., Karlsson H., Olsson R., et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147:614-633.
38. Remberger M., Ackefors M., Berglund S., et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant 2011, 17:1688-1697.
39. Svahn B.M., Alvin O., Ringden O., et al. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation 2006, 82:147-153.